Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y
NCT00698061
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
145
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis B
Interventions
BIOLOGICAL:
HBV-MPL vaccine 208129
BIOLOGICAL:
Engerix™-B
Sponsor
GlaxoSmithKline